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SETBP1 variants occur as somatic mutations in several hematological malignancies such as
atypical chronic myeloid leukemia and as de novo germline mutations in the Schinzel–Giedion
syndrome. Here we show that SETBP1 binds to gDNA in AT-rich promoter regions, causing
activation of gene expression through recruitment of a HCF1/KMT2A/PHF8 epigenetic
complex. Deletion of two AT-hooks abrogates the binding of SETBP1 to gDNA and impairs
target gene upregulation. Genes controlled by SETBP1 such as MECOM are significantly
upregulated in leukemias containing SETBP1 mutations. Gene ontology analysis of deregu-
lated SETBP1 target genes indicates that they are also key controllers of visceral organ
development and brain morphogenesis. In line with these findings, in utero brain electro-
poration of mutated SETBP1 causes impairment of mouse neurogenesis with a profound delay
in neuronal migration. In summary, this work unveils a SETBP1 function that directly affects
gene transcription and clarifies the mechanism operating in myeloid malignancies and in the
Schinzel–Giedion syndrome caused by SETBP1 mutations.
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Recently, we and others demonstrated the involvement ofSETBP1 mutations in several hematological malignancies1–9.In our work, we showed that SETBP1 somatic variants occur
in a 4 amino acid mutational hotspot within the so called SKI-
homology domain. This mutational hotspot is part of a degron
motif that specifies substrate recognition by the cognate SCF-β-
TrCP E3 ubiquitin ligase. SETBP1 mutations cause a functional loss
of the degron motif targeted by SCF-β-TrCP and responsible for the
short half-life of the protein. Therefore, these mutations result in an
increased half-life of the mutated SETBP1 protein causing its
accumulation and inhibition of the PP2A phosphatase oncosup-
pressor through the SETBP1–SET–PP2A axis1.
SETBP1 mutations occurring in the same hotspot were pre-
viously found in a germline disease known as the
Schinzel–Giedion syndrome (SGS)10. Despite the overlap between
the mutations present in hematological disorders and in SGS,
recent data suggest that somatic SETBP1 mutations found in
leukemias are more disruptive to the degron than germline var-
iants responsible for the onset of SGS11. In SGS, germline
SETBP1 mutations occur as de novo variants, causing a severe
phenotype characterized by mental retardation associated with
distorted neuronal layering12, multi-organ development
abnormalities, and higher than normal risk of tumors10.
Although the first studies led to a reliable characterization of
SETBP1 as an oncogene, several elements of SETBP1 activity
were still unclear, in particular: (1) inhibition of PP2A phos-
phatase alone does not explain the SETBP1-dependent phenotype
of SGS10, and (2) SETBP1 possesses three conserved AT-hooks10,
therefore suggesting a role as a DNA-binding protein.
Preliminary evidence that murine Setbp1 is able to bind to
genomic DNA (gDNA) was initially given by Oakley and col-
leagues13: by transducing murine bone marrow progenitors with
high titer retrovirus expressing Setbp1 followed by chromatin
immunoprecipitation (ChIP) experiments, the authors demon-
strated binding of Setbp1 to Hoxa9/10 promoters and upregula-
tion of the two genes. Using a similar murine model,
Vishwakarma and colleagues14 showed binding of Setbp1 to the
Runx1 promoter; this, however, was associated with down-
modulation of RUNX1 expression.
In this study, we analyze the interaction between SETBP1 and
gDNA on a global, unbiased scale and demonstrate that SETBP1
binds DNA in adenine-thymine (AT)-rich promoter regions,
causing activation of gene expression through the recruitment of
a SET1/KMT2A (MLL1) COMPASS-like complex.
Results
SETBP1 as a DNA-binding protein. Cristobal et al. showed a
clear role for SETBP1 as a natural inhibitor of PP2A15. However,
SETBP1 possesses three conserved AT-hook domains10, respon-
sible for binding to the minor groove of AT-rich gDNA regions;
thus their presence suggests a role for SETBP1 as a DNA-binding
protein.
To test this hypothesis, we generated isogenic 293 FLP-In cell
lines harboring wild-type (WT) and mutated (G870S) SETBP1 in
fusion with the V5 tag. Other isogenic models, such as CRISPR-
Cas9, could not be used given the absence of
immunoprecipitation-grade anti-SETBP1 antibodies.
The G870S variant was chosen as it is the most frequent
mutation found in myelodysplastic/myeloproliferative disorders,
together with the D868N1. The G870S line showed similar
SETBP1 transcript levels but increased SETBP1 protein compared
to the WT one (Supplementary Figure 1a, b), as expected1. Anti-
V5 ChIP-Seq experiments revealed a total of 3065 broad genomic
regions as being bound by SETBP1-G870S (Supplementary
Data 1). The presence of broad peaks occurred mainly in AT-
rich regions (Fig. 1a; mean peaks A/T content: 65.8% vs. 59% for
the whole human genome; p < 0.0001) in cells expressing both
SETBP1-G870S and SETBP1-WT. De novo motif discovery
identified a SETBP1 consensus binding site (Fig. 1b; AAAATAA/
T; p= 0.002) largely overlapping the AT-hook consensus motif of
HMGA116 (AAAATA; http://hocomoco.autosome.ru/motif/
HMGA1_HUMAN.H10MO.D), suggesting that SETBP1 binds
gDNA through its AT-hook domains. Querying the Catalog of
Inferred Sequence Binding Preferences (http://cisbp.ccbr.
utoronto.ca/index.php)17 for murine Setbp1 resulted in a very
similar sequence, with an AAT trinucleotide as the core motif
(http://cisbp.ccbr.utoronto.ca/TFreport.php?searchTF=
T008692_1.02), therefore suggesting that the DNA-binding motif
for SETBP1/Setbp1 is conserved across evolution. Independent
ligand-fishing experiments confirmed the ability of SETBP1 to
bind to gDNA (Fig. 1c).
Peak distribution analysis revealed enrichment around pro-
moters (Fig. 1d; 58% and 65% of the total peak count reside at
+/−50 Kb from each transcription start site (TSS) for WT and
G870S, respectively). However, the binding of SETBP1 was not
restricted to promoters but also present in enhancers, exonic,
intronic, and intergenic regions (Fig. 1e). In line with the
quantitative effect of SETBP1 mutations on SETBP1 protein
stability, SETBP1-G870S and SETBP1-WT ChIP-Seq experiments
revealed a global increase of SETBP1-G870S binding across all the
regions tested (Fig. 1e; Jaccard p= 0.046).
Peak annotation identified ectopic binding of SETBP1-G870S
to 277 genes (Supplementary Figure 2a-c; Supplementary Data 2)
resulting in a strong functional enrichment for development-
related biological processes such as nervous system, heart, and
bone development (Fig. 1f). Notably, over one third of the
binding regions lies within either evolutionary conserved regions,
defined as 100 bp gDNA windows characterized by a human-
mouse conservation ≥70%18, or DNase I hypersensitive clusters,
thus suggesting that a dysregulation in their activation could lead
to significant functional consequences (Fig. 1g).
SETBP1 upregulates target genes at the transcriptional level.
To dissect the effect of SETBP1 at the transcriptional level, we
generated RNA-Seq profiles for cells overexpressing SETBP1-
G870S, SETBP1-WT, as well as an Empty control. Comparative
analysis of cells overexpressing G870S vs. WT revealed a very
similar profile (Fig. 2a, b). This finding supports the expected
quantitative mechanism of action of SETBP1 mutations, as pre-
viously proposed1, 3, 11.
This model is further supported by the evidence that virtually
all the activating SETBP1 variants identified so far fall exactly
within the PEST domain and >95% within 4 amino acids of the
extremely short degron linear motif and that the disruption of the
PEST domain causes subsequent impairment of the SETBP1−β-
TrCP axis1, 3, 11. To confirm this hypothesis in the context of
transcriptional regulation, we analyzed the intersection between
SETBP1 peaks generated in our ChIP experiments and ENCODE
transcription factor binding sites (TFBSs). In the presence of
mutated SETBP1, we detected an increase in the total number of
shared TFBS; however, the putative binding partners did not
change between SETBP1-WT and mutated lines (Supplementary
Figure 3). These data highlight the presence of a quantitative
rather than a qualitative effect for SETBP1 mutations, thus
supporting the reduced degradation model.
Subsequent comparative RNA-Seq analysis of SETBP1-G870S
vs. Empty showed the presence of 2687 differentially expressed
genes (DEGs), 57% of which were downregulated and 43%
upregulated (Fig. 2a, b; Supplementary Data 3). The intersection
between genes bound by SETBP1 in promoter regions and DEGs
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(false discovery rate (FDR) < 0.001) revealed 105 co-occurring
genes (Fig. 2c, Supplementary Data 4). Of them, 99 (94.3%; p <
1 × 10−6) were upregulated, suggesting a primary role for SETBP1
as a positive inducer of gene expression (Fig. 2c). Relative
quantification on a subset of target genes (SKIDA1, NFE2L2,
PDE4D, FBXO8, CEP44, COBLL1, BMP5, ERBB4, CDKN1B) on
SETBP1-WT, SETBP1-G870S, and Empty cells by mean of
quantitative polymerase chain reaction (Q-PCR) confirmed the
differential expression detected by RNA-Seq (Fig. 2d).
Functional annotation of DEGs and Gene Set Enrichment
Analyses (Fig. 2e, f) showed significant enrichment for ontologies
related to cell differentiation and tissue development, thus
suggesting that SETBP1-mediated transcriptional deregulation
may play an important role in the onset of SGS10.
SETBP1 is part of a multiprotein epigenetic complex. AT-
hook-containing proteins are often part of large chromatin
remodeling complexes19–21. ChIP-Seq profiles of a set of histone
marks associated with gene expression (H3K4me2, H3K4me3,
H3K9ac, H3K27ac, and H3K36me3) revealed peak distribution
enrichment around the promoter regions for all the tested marks
with the exception of H3K36me3, which was enriched in gene
bodies, as expected (Fig. 3a). Differential enrichment analysis in
SETBP1-G870S vs. Empty showed a correlation between SETBP1
promoter occupancy and increase of H3K4me2 and H3K9ac
(Fig. 3b, c; p= 1 × 10−4 and p= 1.2 × 10−16, respectively). A
significant transcriptional upregulation was detected for the genes
bound by SETBP1-G870S and displaying an increase in
H3K4me2 and H3K9ac, corroborating the hypothesis of SETBP1
being part of a nucleosome-remodeling complex involved in
transcriptional activation (Fig. 3d; Supplementary Data 5). In line
with the previous findings, correlation of SETBP1-binding
regions as well as related epigenetic marks between SETBP1-
G870S and SETBP1-WT was nearly perfect (r= 0.985 and p <
0.00001 for anti-V5; r= 0.873 and p < 0.00001 for anti-H3K9Ac;
Supplementary Figure 4).
Co-immunoprecipitation (Co-IP)/proteomics experiments
directed against SETBP1 (Supplementary Data 6) revealed direct
interaction of both WT and mutated SETBP1 with HCF1, a core
protein of the SET1/KMT2A complex, responsible for H3K4
mono- and di-methylation22. These results were confirmed by
independent immunoprecipitation/western blot experiments
(Fig. 4a) and by acceptor photobleaching fluorescence resonance
energy transfer (FRET) assays (Fig. 4b). In silico linear domain
analysis23 revealed the presence of a putative HCF1-binding motif
(HBM) occurring at position 991–994 of SETBP1 (Supplementary
Figure 5). Deletion of this motif in WT and mutated cells
(SETBP1ΔHBM and SETBP1-G870S-ΔHBM; Supplementary
Figure 6) caused a complete and specific abrogation of
SETBP1/HCF1 interaction in both lines (Fig. 4b); conversely,
the known SETBP1–β-TrCP1 interaction present only in the WT
protein was not affected by the deletion (Fig. 4c). To assess
whether the loss of the SETBP1-HCF1 interaction could result in
the impairment of the SETBP1 transcriptional machinery, we
analyzed by Q-PCR the expression levels of a set of upregulated
genes: the deletion of HBM resulted in a complete normalization
of the expression level for all the tested genes (Fig. 4d; MECOM p
= 0.01; BMP5 p < 0.001, PDE4D p < 0.001, ERBB4 p= 0.036).
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Finally, a direct interaction between SETBP1 and KMT2A was
confirmed by Co-IP experiments (Fig. 4e).
Plant homeodomain (PHD) fingers interact with methylated
histone tails and are typically found in proteins responsible for
the epigenetic modulation of gene expression24. Interestingly,
germline mutations in two PHD family members, PHF8 and
PHF6, have been identified as the cause of two X-linked mental
retardation syndromes, namely Siderius X-linked mental retarda-
tion25 and Borjeson–Forssman–Lehmann syndrome26, and
somatic PHF6 mutations have been found in T cell acute
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lymphoblastic27 and acute myeloid leukemias (AMLs)28. PHF8 is
also responsible for brain and craniofacial development in
zebrafish29. While the role of PHF6 as an epigenetic modulator
is less clear, PHF8 acts as a lysine demethylase. It can bind di- and
tri-methylated H3K4 in the context of KMT2A complexes
through its N-terminal PHD finger24, exerting its demethylating
activity on H4 Lysine 20. ChIP against H4K20me1 revealed a
significant decrease in H4K20 mono-methylation in cells
expressing mutated SETBP1 for all the tested SETBP1 target
genes (Fig. 4f), suggesting that the SETBP1 complex possesses
H4K20 demethylase activity. Co-IP experiments confirmed the
interaction of SETBP1 with PHF8 and PHF6, indicating that both
PHD members are part of the SETBP1 complex (Fig. 4g, h).
Taken globally, these data suggest a link between altered PHD
activity and SGS phenotype.
SETBP1 epigenetic machinery requires functional AT-hooks.
The identification of an AAAATAA/T consensus binding motif
closely resembling that of HMGA1 suggests that SETBP1 may
bind to gDNA thanks to the presence of its AT-hook domains. To
test this hypothesis, we generated new isogenic lines carrying
deletions of the first (SETBP1-G870SΔAT1), second (SETBP1-
G870SΔAT2), and both (SETBP1-G870SΔAT1,2) AT-hook domains
(Supplementary Figure 7). The third AT-hook was not deleted as
it resides within the SET-binding domain. Combined disruption
of AT-hooks 1 and 2 resulted in a marked reduction of mRNA
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SETBP1 ChIP-Seq coverage track and peak alignment to the hg19 reference genome are superimposed to the different histone methylation ChIP-Seq
coverage tracks within the BMP5 locus. d Gene expression heatmap of the subset of SETBP1 targets harboring increased H3K4me2 and H3K9ac activation
marks generated on three Empty and three SETBP1-G870S clones
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expression for all the target genes under analysis (Fig. 4i;
MECOM p= 0.014; BMP5 p < 0.001; PDE4D p < 0.001; ERBB4-
G870SΔAT1p < 0.001; ERBB4-G870SΔAT1,2p= 0.1). ChIP per-
formed on target genes followed by Q-PCR confirmed the same
effect (MECOM p < 0.001; BMP5 p < 0.001; PDE4D p < 0.001;
ERBB4 p= 0.003), indicating that SETBP1 binding to gDNA
depends on the presence of functional AT-hooks (Fig. 4j).
The fact that SETBP1 is commonly found in DNase I
hypersensitive cluster regions together with its ability to interact
with an epigenetic activator complex containing H3K4
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methyltransferase activity suggests that SETBP1 should be able to
control gene expression through modulation of chromatin
accessibility. To test this hypothesis, we generated ATAC-Seq
(assay for transposase-accessible chromatin using sequencing)30
experiments on the isogenic 293 FLP-In Empty, SETBP1-WT,
and SETBP1-G870S cell lines. We assessed the ATAC-Seq signal
in a region comprised between −2000 bp and +10,000 bp from
the TSS of all the human genes. In line with the expected high
accessibility of TSS regions, ATAC-Seq analysis revealed a peak at
TSS in all the lines under test (Supplementary Figure 8a, b;
Supplementary Data 7–9). Subsequently, we investigated whether
a correlation could be found between the intensity of the relative
ATAC-Seq signal in SETBP1-G870S vs. Empty or SETBP1-WT
vs. Empty at TSS and gene bodies and the relative gene
expression, as assessed by RNA-Seq in the same lines. Analysis
at global gene level performed throughout a set of iterations (50)
characterized by progressively more stringent differential expres-
sion fold-change filtering criteria revealed a significant linear
relationship between differential ATAC-Seq signal at TSS and
RNA expression for both SETBP1-G870S and SETBP1-WT
(Supplementary Figure 8c). Taken globally, these data indicate
that genes that are significantly upregulated in the presence of
either WT or mutated SETBP1 exhibit an increased chromosomal
accessibility in their TSS regions as well as in gene bodies.
MECOM is a direct transcriptional target of SETBP1. In 2013,
Makishima and colleagues reported that the presence of mutated
SETBP1 was associated with upregulation of MECOM expres-
sion3; however, a clear mechanistic explanation of this finding
was missing.MECOM, located on the long arm of chromosome 3,
is a transcription factor able to recruit both coactivators and
corepressors31. It is expressed in hematopoietic stem cells, playing
an important role in hematopoiesis and in hematopoietic stem
cell self-renewal32. MECOM is often overexpressed, as a result of
chromosomal translocations, in myelodysplastic syndromes and
in approximately 10% of AML cases, being a strong negative
prognostic marker for therapy response and survival33, 34.
In line with Makishima’s report, differential expression RNA-
Seq (Fig. 5a; p= 0.04 and p= 0.08 for SETBP1-WT and SETBP1-
G870S vs. Empty, respectively) and Q-PCR analyses (Fig. 5b; p=
0.01 and p= 0.001 for SETBP1-WT and SETBP1-G870S vs.
Empty, respectively) showed that MECOM is upregulated in 293
FLP-In cells expressing WT or mutated SETBP1. A similar
upregulation was detected in the human myeloid TF-1 cell line
transduced with SETBP1-G870S (Supplementary Figure 9; p=
0.0001). ChIP-Seq data showed that both SETBP1-WT and
SETBP1-G870S bind to the MECOM promoter, highlighting
MECOM as a direct target of SETBP1 transcriptional activity
(Fig. 5c). MECOM modulates the expression of a significant
number of genes involved in hematopoietic stem cell proliferation
and myeloid differentiation (Supplementary Data 10). In
accordance with its previously observed transcriptional activity35,
we show here that MECOM target genes are also differentially
expressed (p < 0.0001, Fig. 5d) in cells expressing SETBP1-G870S.
To confirm these results in fresh leukemic cells, RNA-Seq and Q-
PCR analyses were performed in 32 atypical chronic myeloid
leukemia (aCML) cases (11 positive and 21 negative for SETBP1
somatic mutations). The results show that SETBP1-positive
patients express higher levels of MECOM (Fig. 5e, f; p=
0.0002) and MECOM target genes (Fig. 5g; p < 0.0001), with
excellent correlation between RNA-Seq and Q-PCR data (Fig. 5f).
Mutated SETBP1 delays neuronal migration to the cortex.
Upon their general developmental delay, Schinzel–Giedion
patients present heavy neurological impairment characterized by
microcephaly, altered neuronal layering, underdeveloped corpus
callosum, ventriculomegaly, cortical atrophy, or dysplasia that
cause seizures and severe mental retardation11, 12. Additionally,
the mRNA of SETBP1 gene is expressed in both germinal (high
level of expression) and differentiated area (low level) of different
brain regions including cerebral cortex (Supplementary Fig-
ure 10). To gain insight into the function of the mutated form of
SETBP1 in nervous system development, we transduced radial
glial progenitors of cerebral cortices of E13.5 mouse embryos with
expression plasmids encoding SETBP1-WT, SETBP1-G870S,
SETBP1-G870SΔAT1,2, and SETBP1-G870S-ΔHBM using an in
utero electroporation system (Fig. 6a)36. The transduced cells and
their progeny can be easily traced along their development thanks
to the green fluorescent protein (GFP) expression. Two days after
the procedure, almost the totality of the SETBP1-G870S electro-
porated cells remained stacked in the deep part of the developing
cortical wall while many control cells (transduced with GFP only)
were already migrating in the outward cortical region where post-
mitotic neurons reside (Fig. 6b; Supplementary Movie 1 and 2).
In addition, in SETBP1-G870S-overexpressing tissue, the apical
domain of the cortical layer where the neural progenitors are
located was severely disorganized as shown by aberrant locali-
zation of TBR2+ intermediate progenitors that lost their typical
strip arrangement in the basal part of the ventricular zone
(Fig. 6c). Five days after surgery, many control GFP+ neurons
were detected in the mature cerebral mantel zone, contributing to
the fiber tract of the corpus callosum (Fig. 6d, arrow), while the
vast majority of cells electroporated with SETBP1-G870S were
incorrectly located at the deepest cortical tissue (65 vs. 32% of the
control condition; t-test p < 0.001 in bins 1–3) with only few
neurons projecting to the contralateral hemisphere through the
corpus callosum (Fig. 6d). In line with the proposed quantitative
model for SETBP1 mutations, overexpression of SETBP1-WT
showed similar, albeit reduced, effects (Fig. 6d). Overexpression
of mutated SETBP1 carrying either AT-hooks 1 and 2 double
Fig. 5 Analysis of MECOM expression and downstream targets. a Box plot showing the RNA-Seq differential expression analysis ofMECOM in the 293 FLP-
In Empty, SETBP1-WT, and SETBP1-G870S cell models. The top and bottom of each box represent the first and third quartile, respectively; the internal line
represents the median; the dot represents the mean. Experiments were performed in triplicate. b Q-PCR analysis of MECOM expression in the 293 FLP-In
Empty, SETBP1-WT, and SETBP1-G870S cell models. The top and bottom of each box represent the first and third quartile, respectively; the internal line
represents the median; the small square represents the mean. Experiments were performed in triplicate; statistical analysis was performed using t-test. c
SETBP1 ChIP-Seq coverage track and peak alignment to the hg19 reference genome (blue tracks) are superimposed to the different histone methylation
tracks and KMT2A (MLL) ChIP-Seq coverage track61 within the MECOM locus. The boxed histogram represents an independent ChIP experiment
performed against the V5 flag in the FLP-In cells followed by a Q-PCR directed against the predicted SETBP1-G870S-binding locus on the MECOM
promoter. ChIP was performed in triplicate; statistical analysis was performed using t-test. d Gene expression heatmap of MECOM target genes in three
Empty/SETBP1-G870S FLP-In clones. e Differential MECOM expression as read counts per million of mapped reads (RPM) in 32 aCML patients carrying
WT (21) or mutated (11) SETBP1. The top and bottom of the box represent the first and third quartile, respectively; the internal line represents the
median. Statistical analysis was performed using t-test. f Linear correlation of MECOM expression as assessed by RNA-Seq (x axis) and Q-PCR (y axis). r
represents the Pearson linear correlation coefficient. g Gene expression heatmap of MECOM target genes in 32 aCML patients carrying WT (21) or
mutated SETBP1 (11). Error bars represent the standard error. *p < 0.05; **p < 0.01; ***p < 0.001
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knockout (SETBP1-G870SΔAT1,2) or deletion of the HCF1-
binding domain (SETBP1ΔHBM) largely restored the normal
migration pattern (Fig. 6d), indicating that the presence of
functional domains responsible for DNA interaction or multi-
protein complex recruitment is required to modulate neuronal
migration. Despite the impaired migration, the cells expressing
SETBP1-G870S retained the capability of differentiating into
neurons as confirmed by the expression of the mature neuronal
marker SATB2 (Fig. 6e). These findings demonstrate that the
increase in SETBP1 levels during brain morphogenesis has a high
impact on the dynamics of both neuronal proliferation and
migration that can be responsible for the neuroanatomical defects
described in SGS.
Discussion
This work describes the results of a next-generation sequencing-
based, unbiased approach performed to investigate the function
of SETBP1 and its pathological variant SETBP1-G870S. We
demonstrate the ability of human SETBP1 to directly bind gDNA
and that the binding occurs preferentially but not exclusively in
gene promoter regions, as SETBP1 has also been detected in
enhancers, exonic, intronic, and intergenic regions. In this work,
we focused on the potential role of SETBP1 as a transcriptional
modulator, showing that SETBP1 interacts with gDNA through
its AT-hook domains, forming a multiprotein complex including
HCF1, KMT2A, PHF8, and PHF6, which results in increased
chromatin accessibility, as assessed by ATAC-Seq (Supplemen-
tary Figure 8), and transcriptional activation. The altered tran-
scription caused by the increased levels of SETBP1-G870S was
also shown to be involved in the pathogenesis of SGS, aCML, and
related myeloid malignancies, as revealed by in utero electro-
poration of SETBP1-G870S in ventricular central nervous system
cells and by the analysis of aCML samples.
Oakley et al. previously showed that, in murine bone marrow,
progenitors transduced with high-titer retrovirus-expressing
Setbp1 are able to bind to Hoxa9/10 and Myb promoters and to
upregulate these genes13, 37. Vishwakarma and colleagues14, using
a similar murine model, demonstrated binding of Setbp1 to the
Runx1 promoter14, which, however, was associated with Runx1
downmodulation. Interestingly, in our human 293 FLP-In model
we found a similar downregulation (Supplementary Figure 11a).
ChIP experiments, however, demonstrated only a very weak
binding of SETBP1 to the human RUNX1 promoter (Supple-
mentary Figure 11b), likely due to the expression of SETBP1
being much lower in our model than in traditional high-titer
retroviral transduction systems or to differences in species spe-
cificity. To test this hypothesis, we repeated ChIP experiments
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using a transient transfection model, achieving a 4.2- and 6.9-fold
increase in SETBP1-WT and G870S expression, respectively,
when compared with FLP-In (Supplementary Figure 11c).
Indeed, ChIP experiments performed using transient SETBP1
transfectants showed a significant increase in the binding to
RUNX1 promoter (Supplementary Figure 11d). This, however,
was accompanied by an increase in RUNX1 expression (Supple-
mentary Figure 11e), confirming that SETBP1 promotes upre-
gulation of gene expression and suggesting that RUNX1
downmodulation is not a direct effect of SETBP1. Further studies
will be required to assess whether the differences between our
model and the murine model developed by Vishwakarma and
colleagues14 are species specific. DEG analysis between SETBP1-
G870S and Empty cells in our FLP-In model and in aCML
patients (11 positive and 21 negative for SETBP1 somatic muta-
tions) failed to reveal significant changes in the expression of
RUNX1, HOXA9/10, or MYB (Supplementary Figure 12), corro-
borating the hypothesis that the effect of SETBP1 as a tran-
scription factor is species/tissue specific.
In line with evidence indicating that KMT2A has strong H3
mono- and di-methylation but very weak tri-methylation activ-
ity22, no significant H3K4me3 enrichment could be found in
promoters occupied by SETBP1, although the intersection
between SETBP1 promoter occupancy and transcriptome analysis
together with the increase in H3K9Ac and the direct interaction
of SETBP1 with PHF8 demethylase reveal that SETBP1 is part of
a transcriptional activator complex. The exact explanation of this
complex histone pattern is still unclear, given also our limited
knowledge about the functions of the H3K4me2 mark. Never-
theless, several lines of evidence suggest that H3K4me2 is strongly
enriched in lineage-specific gene promoters38, 39. The abundance
of genes associated with multi-organ development among those
regulated by SETBP1 is particularly interesting in the context of
SGS, whose hallmark is the presence of multi-organ development
abnormalities. Indeed, analysis of the Gene Ontologies associated
with DEGs in SETBP1-G870S cells highlights the presence of a
much stronger association with SGS than with myeloid malig-
nancies, despite the fact that SETBP1 somatic mutations are
detected in a large number of clonal myeloid disorders1–9. In
aCML and related malignancies, the hyperactivation of the
SETBP1–SET axis caused by the stabilization of mutated SETBP1
protein and leading to the inhibition of the PP2A oncosuppressor
probably plays a major functional role in driving the leukemic
phenotype, while the interaction with gDNA and the subsequent
modulation of gene expression likely plays a critical role in the
onset of SGS, in which the SETBP1-mediated inhibition of PP2A
is probably insufficient to recapitulate the complex phenotype of
the SGS syndrome10. However, the transcriptional activity of
SETBP1 likely contributes to the leukemic phenotype too. In
2013, Makishima and colleagues reported that cases with SETBP1
mutations were characterized by high expression of the MECOM
oncogene3, 40. Here we show that MECOM is a direct target of
SETBP1 transcriptional activity, which explains the original
observation. Interestingly, Goyama and colleagues previously
showed that SETBP1 is one of the genes whose expression is most
strongly reduced in MECOM−/− hematopoietic cells41, sug-
gesting that SETBP1 is also one of the MECOM downstream
targets. Taken together, these findings suggest the presence of a
positive feedback loop occurring between MECOM and SETBP1,
whose biological importance and effects will require further stu-
dies. These findings highlight a potentially critical role for this
transcriptional complex and its downstream effectors in the
oncogenesis of SETBP1-positive myeloid disorders, therefore
suggesting that a strict dichotomous model is too simplistic to
fully recapitulate and explain both phenotypes. It is also impor-
tant to note that, while de novo germline SETBP1 mutations
constitute the only genetic alteration in SGS, somatic SETBP1
mutations are typically present in conjunction with several other
somatic events in myeloid neoplasms, in which SETBP1 muta-
tions usually represent late events3.
In summary, we showed here that SETBP1 is able to recruit a
HCF1/KMT2A/PHF8/PHF6 transcriptional activator complex,
thus identifying SETBP1 as a transcriptional activator, beyond its
original SET-binding activity. Further studies will be required to
gain further insights into this complex network and to dissect the
functional role of SETBP1–gDNA interaction in intergenic
regions.
Methods
Patients. Diagnosis of aCML and related diseases was performed according to the
World Health Organization 2008 classification. All patients provided written
informed consent, which was approved by the institutional ethics committee. This
study was conducted in accordance with the Declaration of Helsinki.
Cell-lines. 293T, TF-1, and the 293 FLP-In™ cell-lines were purchased from ATCC
(Manassas, VA, USA), DSMZ (Braunschweig, Germany), and Thermo Fisher
Scientific (Waltham, MA, USA), respectively, and maintained following the
manufacturers' instructions.
Plasmids and transfections. Stable 293 FLP-In Empty, 293 FLP-In SETBP1wt,
and 293 FLP-In SETBP1-G870S cell lines were prepared cotransfecting pOG44
(Thermo Fisher Scientific) and pFRT-SETBP1 vectors with Fugene6 reagent and
were maintained in standard medium with 100 μg ml−1 Hygromycin. Stable TF-1
cell lines were retrovirally infected using phoenix packaging cells transfected with
10 μg of MIGR1-SETBP1 Gly870Ser or WT or with empty MIGR1 vector using
FuGENE6 (Promega); retroviruses were collected after 3 days of culture. Transient
293T transfectants were prepared using the pcDNA6.2-SETBP1wt, pcDNA6.2-
G870S, or empty vectors1 with Fugene6 reagent (Promega, Madison, WI, USA)
following standard protocols. The deletion of the HBM site (aa991-994;
NM_015559.2) within the SETBP1 coding sequence was performed with the fol-
lowing primers SETBP1_HCF1del_for (CAGCATTTTTCGGATTAATTTTC
CGGTGCCATATATCCAGTATG) and SETBP1_HCF1del_rev (CATACTGGAT
ATATGGCACCGGAAAATTAATCCGAAAAATGCTG); the deletion of the AT-
hooks 1 and 2 were performed using the following primers: SETBP1_ATH1del_for
(CAGTCTTACTGTGATCACTCCACTCACAGTCGAGACGATTCATG),
SETBP1 ATH1del_rev (CATGAATCGTCTCGACTGTGAGTGGAGTGATCACA
GTAAGACTG), SETBP1_ATH2del_for (GTAGGACTTCAGACTTGAA-
GACCATGACAAAGGTGCC), and SETBP1 ATH2del_rev (GGCACCTTTGTC
ATGGTCTTCAAGTCTGAAGTCCTAC) as previously described42. pCGN-
HCF1-fl was a gift from Winship Herr (Addgene plasmid #53309).
ChIP sequencing (ChIP-Seq). ChIP was performed as previously reported43 (GEO
accession number: GSE86335). Briefly, proteins were crosslinked with 0.4% for-
maldehyde and cells were lysed. Chromatin was fragmented with a Bioruptor
sonicator system (Diagenode, SA, USA) and subsequently immunoprecipitated
with H3K4me3 (ab8580, Abcam, UK), H3K4me2 (C15410035C, Diagenode),
H3K36me3 (Ab9050, Abcam), H3K27Ac (Ab4729, Abcam), H3K9Ac (39137,
Active Motif, Carlsbad, CA, USA), and H4K20me1 (Mab147-010, Diagenode)
antibodies or anti-V5 agarose beads (Sigma-Aldrich). After immunoprecipitation,
DNA was purified and libraries were prepared for sequencing following the Illu-
mina ChIP-Seq protocol (TrueSeq ChIP library prep kit IP-202-1012) with an
Illumina HiSeq2500 in single read mode (Galseq, Monza, Italy). Validation of
ChIP-Seq data was performed amplifying the immunoprecipitated DNA with Sybr-
Green Q-PCR. Input was used as a loading control. Primer sequences were:
BMP5_Fw (CAACCCTGCTGGGAAAGAAGAG), BMP5_Rw (TCATCAAGCT
AACTTAGGCACAAC), NFE2L2_Fw (AACCAGAAGAATACAATCCCAATG),
NFE2L2_Rw (AAGAAGTTTCTGCTCATCCTTTGTAG), PDE4D_Fw (CCTT
GAGCCAACCTTCTCCTTC), PDE4D_Rw (CACCCAAAGACATGACCAA
CCTC), SKIDA1_Fw (TTCAAGTATCACGTTACTGTTTGC), SKIDA1_Rw
(GTCACTTATTCAGCCACGCAGAC), COBLL1_Fw (TCTAATTGGTGGCAG
GTTTAAGC), COBLL1_Rw (TGTCTGTCAGGTGTAAAGAATCATC),
ERBB4_Fw (ACAAACTCCTCCAAACTGCTACTG), ERBB4_Rw (GTGATCCA
TTGGAAACTGTAAATGC), RUNX1P2_Fw (CCTATGCAAACGAGCTGAGG),
RUNX1P2_Rw(GCTCTATGAATGAGAGTGCCTG), MECOM_Fw
(CTCCCAAATGTCTTAATCGTGTCG), and MECOM_Rw
(TTCGGACCCTTTGGCTAGATTGTG).
ChIP-Seq analyses were performed using MACS v. 1.4.244 using the –no model
parameter to skip the model building step. The ratio of the intersection and the
similarity of the two genomic interval sets was calculated via bedtools Jaccard
v2.26 statistics45.
Fold enrichment of either SETBP1 or histone methylation ChIP-Seq
experiments in G870S or WT background were calculated with MACS using
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narrow or broad (SETBP1) peak calling parameters46. Transcription factor
association strength and relative fold change were calculated as previously
reported47. Downstream statistics, namely, multivariate analysis with linear
correlation assumptions, were performed with the IBM SPSS statistical package.
ATAC-Seq. Cells (100,000/sample) were washed once in cold phosphate-buffered
saline (PBS) 1×, spun at 800 × g for 5’ at 4 °C and resuspended in cold PBS in the
presence of proteasome inhibitors and incubated on ice for 10’. Cells were cen-
trifuged at 800 × g at 4 °C for 10’ and resuspended in: 2× TD buffer (25 µl), Tn5
Transposase (2.5 µl; Illumina), and water (up to 50 µl). The sample was incubated
at 37 °C for 30’ and purified using the SPRI AMPure XP beads. Post-tagmentation
amplification was performed using Nextera primers (Illumina) and Herculase II
polymerase (Agilent) using a standard protocol. Quality of the ATAC-Seq libraries
was assessed using a Tape Station (Agilent) and by agar gel. Quantification was
performed using a QuBit Fluorometer (ThermoFisher).
ATAC-Seq analysis. ATAC-Seq fastq files were initially aligned to the hg38
human reference genome using BWA48 with standard parameters. BAM files were
sorted and indexed using Samtools49.
BAM files from individual replicates were initially merged together and
subsequently processed using our ATAC-Seq tool. Briefly, all the gene start
positions, gene end positions, chromosome, TSS, and gene strands were annotated
(Gencode24). Coverage counts at single-nucleotide resolution were generated for
each Gene/TSS from basesBeforeTSS (2000) to basesAfterTSS (10,000). Coverage at
each position was then normalized using the total coverage of each input BAM. To
plot ATAC-Seq heatmaps, normalized coverage data were binned (binSize= 200
bp) and sorted in decreasing order according to the intensity of the ATAC signal
throughout the entire region (sum of the binned signals from basesBeforeTSS to
basesAfterTSS). To plot line graphs, normalized counts were summed at individual
bins across the entire gene set from basesBeforeTSS to basesAfterTSS. Final binned
counts were then normalized by the gene set size.
To test for the presence of a correlation between chromatin accessibility and
RNA expression, ATAC-Seq and RNA-Seq data generated from the same lines
were compared using the following approach: normalized ATAC-Seq signal data
generated for a region comprised between basesBeforeTSS (1500) to basesAfterTSS
(5000) for each gene in G870S and Empty lines were initially calculated. A G870S/
Empty coverage ratio was then calculated throughout the entire gene set. In
parallel, normalized G870S/Empty RNA-Seq Log2 fold-change expression ratio
was computed. Log2 fold-change data were filtered in Log2_Threshold_Cycles (50)
iterations with progressively more stringent criteria, by increasing the Log2 fold-
change filter from Log2_Threshold_Start (0) at Log2_Threshold_Step (+0.1 increase
for each Log2_Threshold_Cycle) steps. For each iteration, a Pearson correlation was
generated between normalized ATAC-Seq ratios and filtered RNA-Seq fold
changes.
Code availability. Code of the ATAC-Seq tool and of the Epigenetic Marks
Correlation tool will be made available upon request.
Epigenetic marks correlation tool. Anti-V5 and anti-H3K9Ac 293T-SETBP1-WT
and G870S coverage files were used as input. Coverage was binned (BigWig) in
1000 bp regions for all the ChIP-Seq experiments. Individual bins for all the regions
across the entire genome were paired and used for Pearson correlation analysis as
well as for XY plots.
Oligonucleotide pulldown assay. Biotinylated oligonucleotides were synthesized
by Metabion International AG (Steinkirchen, Germany). Target and non-target
(unrelated) oligonucleotides were designed according to ChIP-Seq from SETBP1
bound (target-T, chr6: 55,742,037-55,742,136; hg19) and unbound (unrelated-U,
chr6:55,775,477-55,775,576; hg19) regions. In the pulldown experiment, 25 µl of
Pierce-streptavidin magnetic beads (Thermo Fisher Scientific) were washed using a
magnetic stand and resuspended in 200 µl of B/W buffer (10 mM Tris HCl, pH 7.5,
1 mM EDTA, 2M NaCl). Each double-stranded biotinylated DNA probe (200 nM)
was bound to the beads for 20 min at room temperature (RT) on a rotating device.
One sample without probe was used as a control for unspecific binding. Beads were
washed with TE buffer and resuspended in 100 µl of BS/THES buffer (22 mM Tris
HCl, pH 7.5, 4.4 mM EDTA, 8.9% Sucrose, 62 mM NaCl, 10 mM Hepes, 5 mM
CaCl2, 50 mM KCl, 12% Glycerol) supplemented with HALT protease inhibitor
cocktail (Thermo Fisher Scientific). In all, 15 µg of nuclear extract from 293 FLP-In
transfectants was diluted in 400 µl of BS/THES buffer and, after collecting 30 µl as
INPUT fraction, was added to the beads together with 1 µg of non-specific DNA
competitor LightShift Poly(dI-dC) (Thermo Scientific). Samples were incubated at
4 °C for 30 min on a rotating device. Beads were then washed four times with BS/
THES buffer supplemented with 1 µg of Poly(dI-dC). Final wash was done with
500 µl of buffer (100 mM NaCl, 25 mM Tris HCl) after incubation for 1 min on a
rotating device at RT. Elution of bound proteins was performed with 50 µl of
Laemmli Buffer. Lamin-B1 was used as a loading control.
Co-immunoprecipitation. One hundred million HEK 293T cells were transiently
transfected with pcDNA 6.2 V5-SETBP1-WT, SETBP1 G870S, or with the empty
vector as control. Forty eight hours after transfection, cells were collected, washed
twice with cold PBS, lysed in Buffer 1 (Pipes, pH 8.0, 5 mM, KCl 85 mM, NP-40
0.5%), supplemented with protease inhibitors (Halt™ Protease Inhibitor Cocktail,
Thermo Fisher Scientific), kept for 10 min on ice, homogenized with douncer
homogenizer (10 hits), and centrifuged at 700 × g for 10 min. The pellet was then
resuspended in Buffer 2 (Tris HCl, pH 8.0, 50 mM, sodium dodecyl sulfate 0.1%,
deoxicholate 0.5%) supplemented with protease inhibitors, sonicated with Bior-
uptor Next Gen (Diagenode) (5 cycles 30 s ON, +30 s OFF) to promote gDNA
disruption and centrifuged at 18,000 × g for 10 min. The supernatant representing
the nuclear fraction was quantified with Bradford assay and a total of 1 µg of
protein was loaded on 100 µl V5-agarose beads (Sigma-Aldrich) and incubated
under rotation overnight at 4 °C. Beads were then washed three times with PBS
+protease inhibitors, and elution was performed with 7M Urea, 2 M Thiourea,
and 4% CHAPS for subsequent mass spectrometric analysis or with Laemmli buffer
for western blot analysis. All chemicals were purchased from Sigma Aldrich.
Immunoblot analysis. Primary antibodies were V5 (ab27671 330 Abcam, Cam-
bridge, UK; dilution 1:2000), HCF1 (A301-399A Bethyl Laboratories, Inc., Mon-
tgomery, TX, USA; dilution 1:1000), MLL1 (14689 Cell Signaling Technology,
Danvers, MA, USA; dilution 1:1000), PHF8 (A301-772A Bethyl Laboratories, Inc.,
Montgomery, TX, USA; dilution 1:500), and PHF6 (A301-451A Bethyl Labora-
tories, Inc., Montgomery, TX, USA; dilution 1:500). Secondary antibody was anti-
mouse anti-rabbit horseradish peroxidase conjugated (Biorad, Hercules, CA, USA).
The uncropped scan of western blots related to PHF6 immunoprecipitation are
shown in Supplementary Figure 13 as an example.
Proteomics data analysis. The protein samples were digested in Amicon Ultra-0.5
centrifugal filters using modified FASP method50. The peptides were separated with
the nanoAcquity UPLC system (Waters) equipped with a 5-µm Symmetry C18
trapping column, 180 µm×20mm, reverse-phase (Waters), followed by an analy-
tical 1.7-µm, 75 µm×250 mm BEH-130 C18 reversed-phase column (Waters), in a
single-pump trapping mode. The parameters of the HD-MSE runs were described
previously51. Protein identifications were performed with ProteinLynx Global
Server (PLGS v3.0) as described51. Database searches were carried out against
UniProt human protein database (release_07072015, 71907 entries) with Ion
Accounting algorithm and using the following parameters: peptide and fragment
tolerance: automatic, maximum protein mass: 500 kDa, minimum fragment ions
matches per protein: 7, minimum fragment ions matches per peptide: 3, minimum
peptide matches per protein: 1, primary digest reagent: trypsin, missed cleavages
allowed: 2, fixed modification: carbamidomethylation C, variable modifications:
deamidation (N, Q), oxidation of Methionine (M) and FDR < 4%.
Immunofluorescence microscopy. Transfected HEK 293 cells, seeded on glass
coverslips coated with poly-D-lysine (0.1 mgml−1), were washed twice with PBS
and fixed for 10 min at 25 °C with 4% (w/v) p-formaldehyde in 0.12 M sodium
phosphate buffer, pH 7.4, incubated for 1 h with primary antibodies in GDB buffer
[0.02 M sodium phosphate buffer, pH 7.4, containing 0.45M NaCl, 0.2% (w/v)
bovine gelatin] followed by staining with conjugated secondary anti IgG antibodies
for 1 h. After two washes with PBS, coverslips were mounted on glass slides with a
90% (v/v) glycerol/PBS solution.
FRET. FRET measurements were performed with the laser-induced acceptor
photobleaching method52, 53. In our experimental set-up, FRET couples analyzed
were made up of transiently transfected GFP-fused SETBP1 WT or mutated forms
in combination with transiently transfected Flag-tagged β-TrCP or endogenous
HCF1. Forty eight hours after transfection, HEK 293 cells were labeled with proper
primary and secondary antibodies and imaged for FRET analysis. Used FRET
couples were GFP signal as donor fluorochrome and Alexa Fluor 555-conjugated
secondary antibodies as acceptor fluorochrome54. Briefly, three images were cap-
tured before bleaching in the 488 nm and the 561 nm channels using the line-by-
line sequential mode without any averaging steps to reduce basal bleaching.
Bleaching of the acceptor was performed within region of interest (ROI) identified
in the nuclear areas with a positive colocalization between the FRET couples using
30 pulses of a full power 20 mW 561-nm laser line (each pulse 1.28 µs/pixel). After
bleaching, seven images were acquired in the same channels without any time delay
to obtain a full curve. The number of bleaching steps, laser intensity, and acqui-
sition parameters were held constant throughout each experiment. FRET signal
was quantified by measuring the average intensities of ROIs in the donor and
acceptor fluorochrome channels before and after bleaching using the ImageJ
software (http://rsbweb.nih.gov/ij/). To determine any change of fluorescence
intensities not due to FRET occurring during the measurements, a distinct
unbleached sentinel ROI of approximately the same size of the bleached ROI was
measured in parallel, and all the results were normalized according to the back-
ground bleaching recorded in the sentinel. Proper controls were performed to
verify that no artefacts were generated in the emission spectra throughout the
experimental set-up due to sample overheating. Twenty measurements from three
different experiments were performed for each experimental condition.
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RNA-Seq. RNA libraries were generated starting from 1 µg of total RNA extracted
from 5 × 106 cells using TRIzol (Invitrogen, Life Technologies). RNA quality was
assessed by using a Tape Station instrument (Agilent). To avoid over-
representation of 3′-ends, only high-quality RNA with a RNA Integrity Number ≥8
was used. RNA was processed according to the TruSeq Stranded mRNA Library
Prep Kit protocol. The libraries were sequenced on an Illumina HiSeq 3000 with 76
bp paired-end reads using Illumina TruSeq technology (GEO accession number:
GSE86335).
Image processing and basecall was performed using the Illumina Real Time
Analysis Software. Fastq files were aligned to the human genome (GRCh38/hg39)
by using STAR55, a splice junction mapper for RNA-Seq data, together with the
corresponding splice junctions Ensembl GTF annotation, using the following
parameters:
--runThreadN 8 --outReadsUnmapped Fastx --outFilterType BySJout
--outSAMattributes NH HI AS nM MD --outFilterMultimapNmax 20
--alignSJoverhangMin 8 --alignSJDBoverhangMin 1 --outFilterMismatchNmax
999 --outFilterMismatchNoverLmax 0.04 --alignIntronMin 20 --alignIntronMax
1000000 --alignMatesGapMax 1000000 --alignTranscriptsPerReadNmax 100000
--quantMode TranscriptomeSAM GeneCounts --limitBAMsortRAM 16620578182
--outSAMtype BAM SortedByCoordinate --chimSegmentMin 20
--chimJunctionOverhangMin 10.
Quantitative real-time PCR. Total RNA was extracted with Trizol reagent fol-
lowing standard protocol (Thermo Fisher Scientific). One microgram of RNA was
used to synthesize cDNA using Reverse Transcription Reagents (Thermo Fisher
Scientific) after pretreatment with DNAseI to avoid contamination from gDNA.
Real-time Q-PCR was performed using TaqMan® Brilliant II QPCR Master Mix
(Agilent Technologies, Santa Clara, CA, USA) on a Stratagene-MX3005P (Agilent
Technologies, Santa Clara, USA) under standard conditions. The housekeeping
gene GUSB was used as an internal reference43. TaqMan® Gene Expression Assays
(Thermo Fisher Scientific) were used: SKIDA1 (Hs01096520), NFE2L2
(Hs00975961), PDE4D (Hs03988495), FBXO8 (Hs00942619), CEP44
(Hs00604612), COBLL1 (Hs01117513), BMP5 (Hs00234930), ERBB4
(Hs00955525), CDKN1B (Hs01597588), SETBP1 (Hs00210203), RUNX1
(Hs01021971), MECOM (Hs00602795).
Differential expression analysis. The gene counts generated by the --quantMode
GeneCounts parameter were used to calculate gene expression. All the subsequent
steps were performed using R scripts. These scripts were automatically generated
through metaprogramming, using a dedicated tool (StarCounts2DESeq2) devel-
oped by RP using C# as metalanguage. Differential expression analyses were per-
formed using DESeq256. Analysis of DEGs characterized by the co-occurrence of
both H3K4me2 and H3K9Ac marks was performed by multivariate regression
analysis using the following filtering criteria: transcription factor and histone mark
relative coverage enrichment >0.5 (log2 FC G870S/Empty); differential gene
expression p-value < 0.05 (G870S vs. Empty, DESeq2).
In utero electroporation. SETBP1-G870S was cloned in the pCAG expression
vector57. In utero electroporation was carried out at E13.5 to target the expression
vectors into the ventricular radial glial cells of the mouse embryos, as previously
described58, 59. Briefly, uterine horns of E13.5 pregnant dams were exposed by
midline laparotomy after anesthetization with 312 mg kg−1 Avertin. DNA plasmid
(1 µl, corresponding to 3 µg) mixed with 0.03% fast-green dye in PBS was injected
into the telencephalic vesicle using a micropipette pulled through the uterine wall
and amniotic sac. Platinum tweezer-style electrodes (7 mm) were placed outside
the uterus over the telencephalon, and four pulses of 40 mV for 50 ms were applied
at 950 ms intervals using a BTX square wave electroporator. The uterus was then
placed back into the abdomen, the cavity was filled with warm sterile PBS, and the
abdominal muscle and skin incisions were closed with silk sutures.
All experiments were conducted after approval and following the guidelines of
animal care and use committee from San Raffaele Scientific Institute.
MECOM analysis. To identify MECOM direct targets among the SETBP1 DEGs,
we took advantage of previously published RNA-Seq and ChIP-Seq data in the
context of MECOM overexpression35. The resulting genes were functionally
annotated with FunRich60 and filtered in accordance with their expression within
the bone marrow (Hypergeometric enrichment test p= 0.0013), thus resulting in a
total of 23 MECOM direct targets.
Data availability. All relevant sequencing data are available at the NCBI GEO
Server, accession code: GSE86335.
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